CDK4/6抑制剂相关的平均体质体积变化:预测转移性乳腺癌存活率的潜在参数?
Atila Yildirim1, Mustafa Emre Duygulu2, Evren Fidan2
1Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, Turkiye.
概括
在乳腺癌患者中,CDK4/6抑制剂会增加平均体积 (MCV). 然而,MCV的增加与改善的无进展生存期 (PFS) 或总生存期 (OS) 并没有显著相关.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 激素受体阳性,HER2阴性转移性乳腺癌的治疗通常涉及CDK4/6抑制剂.
- 红细胞平均体积 (MCV) 是一个完全血清参数,可能会受到癌症治疗的影响.
- 在CDK4/6抑制剂治疗期间MCV变化的预后或预测意义尚未得到充分确立.
研究的目的:
- 研究CDK4/6抑制剂对转移性乳腺癌患者的MCV的影响.
- 确定MCV的变化是否与无进展生存期 (PFS) 和整体生存期 (OS) 相相关.
主要方法:
- 74名HR+/HER2-转移性乳腺癌患者的回顾性分析,这些患者接受了CDK4/6抑制剂治疗.
- 在基线和治疗后三个月记录了MCV水平.
- 计算了MCV (ΔMCV) 的中位变化,并将PFS和OS的组之间进行了比较.
主要成果:
- 用CDK4/6抑制剂治疗导致MCV中位数从90.4增加到95.5.
- 三个月后 ΔMCV 的中位数为 7.15.
- 在 ΔMCV ≥7.15 和 ΔMCV <7.15.15 的患者之间,没有观察到 PFS (16.53 与 15.26 个月) 或 OS (21.46 与 17.83 个月) 的统计学上显著差异.
结论:
- CDK4/6抑制剂与转移性乳腺癌患者的MCV增加有关.
- 观察到的MCV的增加并没有与改善的PFS或OS显著相关.
- 需要进一步的研究来澄清MCV的上升是否在这种情况下作为预后或预测标记.
相关概念视频
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:21Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340